Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis

INTRODUCTION: Alpha 1-antitrypsin deficiency (AATD) is a genetic disorder which reduces serum alpha 1-antitrypsin (AAT or alpha1-proteinase inhibitor, A1PI) and increases the risk of chronic obstructive pulmonary disease (COPD). Management strategies include intravenous A1PI augmentation, and, in so...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, Michael A., Runken, Michael C., Davis, Angela M., Johnson, Michael P., Stone, Glenda A., Buikema, Ami R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910458/
https://www.ncbi.nlm.nih.gov/pubmed/29616482
http://dx.doi.org/10.1007/s12325-018-0690-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910458/
https://www.ncbi.nlm.nih.gov/pubmed/29616482
http://dx.doi.org/10.1007/s12325-018-0690-4

Ejemplares similares